Skip to main content
SYNLAB AG logo

SYNLAB AG — Investor Relations & Filings

Ticker · SYAB ISIN · DE000A2TSL71 LEI · 984500883BA5AQ14C037 F Human health and social work activities
Open in API
Filings indexed 152 across all filing types
Latest filing 2023-03-16 Earnings Release
Country DE Germany
Listing F SYAB

About SYNLAB AG

https://www.synlab.com/

SYNLAB AG is a leading provider of medical laboratory diagnostic services. The company offers a comprehensive portfolio of over 5,000 routine and specialty tests across various medical disciplines, including human genetics and anatomical pathology. Its services provide essential diagnostic information for doctors, clinics, and patients, playing a vital role in clinical decision-making throughout the entire patient care process, from prevention and diagnosis to treatment and monitoring.

Recent filings

Filing Released Lang Actions
SYNLAB AG: SYNLAB delivers robust underlying growth in FY 2022
Earnings Release Classification · 100% confidence The document is titled 'SYNLAB AG: SYNLAB delivers robust underlying growth in FY 2022' and explicitly states it announces its 'audited FY 2022 results today'. It contains detailed financial tables for FY 2022 vs FY 2021, discusses revenue, adjusted EBITDA, net profit, and provides an outlook for FY 2023. This content strongly indicates a comprehensive annual financial report summary. Although it mentions the 'SYNLAB Annual Report 2022' is available for download, the document itself is the primary announcement of the full-year audited results, which aligns best with the definition of an Annual Report (10-K), even if it's a press release summarizing the 10-K filing. Given the depth of audited annual figures and the reference to the 'Annual Report', 10-K is the most appropriate classification for the underlying content being summarized, distinguishing it from a brief Earnings Release (ER) or an Interim Report (IR). FY 2022
2023-03-16 English
SYNLAB AG: Extension of the appointment of Mathieu Floreani as CEO and Sami Badarani as CFO
Board/Management Information Classification · 100% confidence The document is an 'Ad-hoc' announcement dated March 15, 2023, explicitly titled 'SYNLAB AG: Extension of the appointment of Mathieu Floreani as CEO and Sami Badarani as CFO'. This content directly relates to changes in senior management positions (CEO and CFO appointments/extensions). According to the definitions, this falls under 'Board/Management Information' (Code: MANG). The document is short and is a direct announcement, not a report itself, confirming the classification based on content.
2023-03-15 English
SYNLAB AG: Non-binding expression of interest by Cinven for acquisition offer at an indicative offer price of 10.00 Euro per SYNLAB share
M&A Activity Classification · 100% confidence The document is an 'Ad-hoc' announcement dated March 13, 2023, disclosing a 'Non-binding expression of interest by Cinven for acquisition offer'. This clearly relates to a potential merger or takeover activity involving SYNLAB AG. Based on the provided definitions, the category 'M&A Activity (Code: TAR)' is the most appropriate fit, as it covers 'Announcements and documents related to merger proposals or takeover bids.' The document is short and is a direct announcement of the event, not a comprehensive report.
2023-03-13 English
SYNLAB AG: SYNLAB reports trading update for FY 2022 and revises FY 2023 guidance from lower COVID-19 testing
Earnings Release Classification · 100% confidence The document is titled "SYNLAB AG: SYNLAB reports trading update for FY 2022 and revises FY 2023 guidance from lower COVID-19 testing" and contains preliminary financial figures for the full year 2022 and updated guidance for FY 2023. It explicitly states it is a 'trading update' and provides key financial highlights (revenue, margin) before the final audited reports. This structure—a preliminary announcement of financial results for a period—aligns best with the Earnings Release (ER) definition, which covers the initial announcement of periodical financial results (key highlights only). Although it contains guidance revision, the core function is reporting the period's performance update. It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR), as it focuses on summarizing the year-end performance update and outlook. FY 2022
2023-02-06 English
SYNLAB AG: SYNLAB revises FY 2023 guidance from lower COVID-19 testing volumes
Earnings Release Classification · 100% confidence The document is dated February 6, 2023, and is classified as 'Ad-hoc' and discloses 'inside information acc. to Article 17 MAR'. The core content involves SYNLAB AG revising its financial guidance for FY 2023 (revenue and adjusted EBITDA margin) due to lower COVID-19 testing volumes. This is a direct announcement of updated financial expectations and performance outlook, which aligns best with an Earnings Release (ER) which covers periodical financial results/updates, or potentially a Regulatory Filing (RNS) if it were a general announcement. However, since it specifically details revised revenue and margin expectations, it functions as an immediate release of key financial performance indicators, fitting the 'ER' definition better than the general 'RNS' fallback, even though it's not explicitly labeled 'Earnings Release'. It is not a full report (10-K or IR), nor a transcript (CT), nor a management discussion (MDA). Given the nature of immediate guidance revision, ER is the most appropriate fit among the specific financial codes. FY 2023
2023-02-06 English
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021
Audit Report / Information Classification · 95% confidence The document is titled 'Finanzbericht' (Financial Report) and contains an 'Einstandserklärung' (Declaration of Assumption of Losses) related to German corporate law (§ 302 Abs. 1 AktG) and accounting consolidation (§ 264 Abs. 3 HGB). It lists numerous subsidiaries and confirms the existence of control and profit/loss transfer agreements ('Beherrschungs- und Gewinnabführungsverträgen'). This type of declaration, detailing the structure for consolidated financial statements and loss absorption obligations, is a specific disclosure required in German statutory financial reporting, often accompanying the Annual Report (10-K equivalent) or an Audit Report. Given the focus on the legal structure underpinning consolidated financials rather than the full financial performance itself (which would be a 10-K or IR), and its specific nature related to accounting principles and group structure, it aligns best with the 'Audit Report / Information' category (AR), which covers applied accounting principles and regulatory stress tests, or potentially Governance (CGR). However, the explicit reference to loss absorption (§ 302 AktG) and the list of subsidiaries for consolidation purposes strongly suggests it is a component of the statutory financial statements disclosure package. Since it is not the full annual report (10-K) but a specific statutory declaration related to accounting consolidation, AR is the most appropriate fit among the provided options, as it covers specific regulatory/accounting disclosures outside the main annual filing. FY 2021
2023-02-01 German

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.